Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)
2022年3月14日 - 10:34PM
Edgar (US Regulatory)
Filed Pursuant to Rule
424(b)(2)
Registration No.
333-232144
 |
 |
Amendment No. 1 dated March 14, 2022 to the Pricing Supplement
dated October 21, 2021 to the
Prospectus dated August 1, 2019, the
Prospectus Supplement dated August 1, 2019 and the Prospectus
Supplement Addendum dated February 18, 2021
|
iPath® Series B S&P 500® VIX Short-Term
FuturesTM ETN
This amendment No. 1 amends and supplements the original pricing
supplement dated October 21, 2021 (the “Pricing Supplement”)
with respect to the iPath® Series B S&P
500® VIX Short-Term FuturesTM
Exchange-Traded Notes (Ticker: VXX) (the “ETNs”) and does
not pertain to any other series of exchange-traded notes described
therein. The terms of the ETNs are as described in the Pricing
Supplement and include the specific amendments described below.
Terms used but not defined herein have the meanings given to them
in the Pricing Supplement.
No Further Sales or Issuances: Effective as of the open
of trading on March 14, 2022, we will suspend, until further
notice, any further sales from inventory and any further issuances
of the ETNs. As a result of this modification, the Pricing
Supplement is amended to reflect this suspension.
Risk Factors: As described in the Pricing Supplement, under
the heading “Risk Factors ― The Market Value of Each
Series of ETNs May Be Influenced by Many Unpredictable Factors,”
the market value of the ETNs may be influenced by, among other
things, the levels of supply and demand for such ETNs. It is
possible that this suspension may influence the market value of the
ETNs. Barclays Bank PLC believes that the limitations on issuance
and sale implemented may cause an imbalance of supply and demand in
the secondary market for the ETNs, which may cause the ETNs to
trade at a premium or discount in relation to their indicative
value. Therefore, any purchase of the ETNs in the secondary market
may be at a purchase price significantly different from their
indicative value. In particular, paying a premium purchase
price over the indicative value of the ETNs could lead to
significant losses in the event you sell your ETNs at a time when
such premium is no longer present in the marketplace or if we
redeem the ETNs at our discretion. Investors should consult their
financial advisors before purchasing or selling the ETNs,
especially ETNs trading at a premium over their indicative value.
Furthermore, if you sell your ETNs at a price which reflects a
discount below the intraday indicative value, you may experience a
significant loss.
You may lose all or a substantial portion of your investment
within a single day if you invest in the ETNs. Any payment on the
ETNs at or prior to maturity, including any repayment of principal,
is not guaranteed by any third party and is subject to both the
creditworthiness of Barclays Bank PLC and to the exercise of any
U.K. Bail-in Power by the relevant U.K. resolution authority. If
Barclays Bank PLC were to default on its payment obligations or
become subject to the exercise of any U.K. Bail-in Power (or any
other resolution measure) by the relevant U.K. resolution
authority, you might not receive any amounts owed to you under the
ETNs. See “Consent to U.K. Bail-in Power” and “Risk Factors” in the
Pricing Supplement and “Risk Factors” in the accompanying
prospectus supplement for more information.
The ETNs are intended to be trading tools for sophisticated
investors to manage daily trading risks and are only suitable for a
very short investment horizon. The ETNs may not be suitable
for all investors and should be used only by investors with the
sophistication and knowledge necessary to understand the risks
inherent in the Index, the futures contracts that the Index tracks
and investments in volatility as an asset class generally.
Investors should consult with their broker or financial advisor
when making an investment decision and to evaluate their investment
in the ETNs and should actively manage and monitor their
investments in the ETNs throughout each trading day.
The ETNs are not deposit liabilities of Barclays Bank PLC and
are not insured by the United States Federal Deposit Insurance
Corporation or any other governmental agency of the United States,
the United Kingdom or any other jurisdiction.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these ETNs or
determined that this amendment No. 1 or the Pricing Supplement is
truthful or complete. Any representation to the contrary is a
criminal offense.

Amendment No. 1 dated March 14, 2022 to the Pricing Supplement
dated October 21, 2021
You should read this amendment
No. 1 and the Pricing Supplement together with the prospectus dated
August 1, 2019, as supplemented by the prospectus supplement dated
August 1, 2019 relating to our Global Medium-Term Notes, Series A,
of which these ETNs are a part, and the prospectus supplement
addendum dated February 18, 2021. You may access these documents on
the SEC website at www.sec.gov as follows (or if such address has
changed, by reviewing our filings for the relevant date on the SEC
website):
|
· |
Prospectus dated August 1, 2019: |
http://www.sec.gov/Archives/edgar/data/312070/000119312519210880/d756086d424b3.htm
|
· |
Prospectus Supplement dated August 1, 2019: |
http://www.sec.gov/Archives/edgar/data/312070/000095010319010190/dp110493_424b2-prosupp.htm
|
· |
Prospectus Supplement Addendum dated February 18, 2021: |
http://www.sec.gov/Archives/edgar/data/312070/000095010321002483/dp146316_424b3.htm

iPath Series B S&P 500 V... (AMEX:VXX)
過去 株価チャート
から 6 2022 まで 7 2022
iPath Series B S&P 500 V... (AMEX:VXX)
過去 株価チャート
から 7 2021 まで 7 2022